News | Image Guided Radiation Therapy (IGRT) | April 30, 2018

New MR pulse sequences and imaging enhancements provide cutting-edge tumor and healthy tissue visualization for MR-guided radiotherapy

ViewRay Unveils New Soft Tissue Visualization Technologies for MRIdian Linac

April 30, 2018 — ViewRay Inc. announced new magnetic resonance imaging (MRI) technologies under development for its MRIdian Linac radiotherapy system. Designed to improve tumor and soft tissue visualization, these enhancements to MRIdian's SmartVision MR image guidance are expected to further improve the precision by which radiation is delivered to treat cancer.

MRIdian's SmartVision allows oncologists to visualize tumors and surrounding organs with diagnostic-quality MR imaging during treatment delivery. Building on the current technology are new T1w and T2w MR pulse sequences, both being developed to improve high-definition visualization and enhance the contrast between cancerous and healthy tissues. Also being developed for MRIdian's SmartVision, diffusion weighted imaging (DWI) may be used to distinguish between tumor and normal tissues and potentially assess and predict tumor response to radiation therapy.

Other enhancements to MRIdian's SmartVision include a 2-times increase in MR imaging speed as compared to previous generation systems, stepping up from 4 frames to 8 frames per second. The latest enhancements under development also include 2 times higher image resolution and a 2 times improvement in MR signal-to-noise ratio (SNR) for brighter, more detailed anatomical imaging.

MRIdian continuously detects the shape and location of tumors and organs-at-risk (OAR) in real-time, and automatically turns radiation beams on and off when positional changes occur. Enabled by faster, higher-resolution imaging, the next-generation SmartVision will further support the clinician's ability to visualize healthy tissue and target the tumor.

ViewRay demonstrated the new MR pulse sequences, along with increased imaging speed and resolution, during the annual meeting of the European Society for Radiotherapy and Oncology (ESTRO), April 21-24 in Barcelona, Spain.

The new pulse sequences, increased image resolution and imaging frame rates are currently a technology under development and only available for sales in the European Economic Area. They are works in progress and are not available for commercial sales in the United States.

For more information: www.viewray.com

 


Related Content

News | Contrast Agents

April 23, 2026 — On April 23, GE HealthCare announced the first patient has been dosed in the international, multi ...

Time April 23, 2026
arrow
News | Radiology Imaging

April 20, 2026 — Bracco Imaging has announced a strategic alliance with NYU Langone Health to advance innovation in ...

Time April 23, 2026
arrow
News | Radiology Business

April 10, 2026 — The radiation therapy team at The Ohio State University Wexner Medical Center, The James Cancer ...

Time April 10, 2026
arrow
News | Radiology Imaging

April 7, 2026 — Onvida Health and Siemens Healthineers have entered a 10-year Value Partnership¹ designed to bring the ...

Time April 09, 2026
arrow
News | Radiology Business

March 31, 2026 — Radon Medical Imaging, a medical imaging equipment maintenance and repair services company, has has ...

Time March 31, 2026
arrow
News | Radiology Imaging

March 26, 2026 — GE HealthCare has announced a renewed research collaboration with Stanford Medicine Department of ...

Time March 30, 2026
arrow
News | FDA

March 20, 2026 — Siemens Healthineers recently announced its Varian TrueBeam radiotherapy systems, which include ...

Time March 24, 2026
arrow
News | Radiology Education

March 17, 2026 – The Center for Radiology Education (CRE) has announced a nationwide initiative to provide scholarships* ...

Time March 17, 2026
arrow
News | Radiology Business

March 12, 2026 — DelveInsight's has released its latest Diagnostic Imaging Equipment Market Insights report. The in ...

Time March 13, 2026
arrow
Feature | Artificial Intelligence | Kyle Hardner

Once considered an adjunct brain cancer therapy and a last-resort treatment, noninvasive radiosurgery has evolved ...

Time March 09, 2026
arrow
Subscribe Now